EichorEICHOR
Location: Antwerp Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Antwerp

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Observational Study Protocol: LIVER-R
Phase N/A · AstraZeneca · NCT06252753Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
NA · Antwerp University Hospital · University Hospital, Geneva · NCT06207383Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation
NA · Universitair Ziekenhuis Antwerpen · University Hospital of Leuven Leuven · NCT07726056Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Antwerp University Hospital · Princess Maxima Center for Pediatric Oncology · NCT05327894Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Phase 3 · Lakefront Biotherapeutics NV · NCT06652633Conservative Endometrioma Surgery
NA · GZA Sint-Augustinus · Universitaire Ziekenhuizen KU Leuven · NCT04151433A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · Merck Sharp & Dohme LLC · NCT07216703A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary
Phase N/A · UZA (Antwerp University Hospital) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT06686615A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Sele
NA · GZA Antwerpen · Alimentiv Inc. · NCT07363044Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/Phase 2 · OSE Immunotherapeutics · NCT05751798Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Eli Lilly and Company · NCT06890598A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 4802 · Turning Point Therapeutics, Inc. · NCT03093116A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child
Phase 3 · Bayer · NCT07192952Visualization of Inspiratory Effort and Respiratory Mechanics to Promote Lung- and Diaphragm Protective Ventilation
NA · University Hospital, Antwerp · NCT05459116A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Dia
Phase 3 · Eli Lilly and Company · NCT07222332A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Regeneron Pharmaceuticals · NCT06091865Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Phase 4 · AZ Monica · University Hospital, Antwerp · NCT05701241A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase 3 · UZ Antwerpen · Longboard Pharmaceuticals · NCT06660394Validation of the O-bridge Protocol: a Prospective, Multicenter Trial
Phase N/A · Ziekenhuis Netwerk Antwerpen · AZ Sint-Jan AV · NCT04007783A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · ZNA Cadix · Celgene · NCT05519085Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Act
Phase 2/Phase 3 · KU Leuven · NCT06782412Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Phase 3 · Eli Lilly and Company · NCT07353931A Study With CIT-013 in RA Patients
Phase 2 · BE-02 · Citryll BV · NCT06567470Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
NA · University Hospital, Antwerp · NCT06278844A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Live
Phase 1 · Bayer · NCT06764316Genotype-phenotype Correlation Study of Presymptomatic and Symptomatic DFNA9 Patients
Phase N/A · University of Antwerp · Jessa Hospital · NCT03716908Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
Phase N/A · University Hospital Antwerp · Universitaire Ziekenhuizen KU Leuven · NCT07727694Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosi
Phase 3 · UZ Antwerpen · Takeda · NCT05677971A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Phase 3 · Hoffmann-La Roche · NCT07416604
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.